Andrew Cheng - 03 Jan 2022 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
President & CEO, Director
Signature
/s/ Jonathan Young, Attorney-in-Fact
Issuer symbol
AKRO
Transactions as of
03 Jan 2022
Net transactions value
+$32,595
Form type
4
Filing time
04 Jan 2022, 20:21:56 UTC
Previous filing
10 Dec 2021
Next filing
02 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $32,595 +53,000 +21% $0.6150* 308,996 03 Jan 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Employee Stock Option (Right to Buy) Options Exercise $0 -53,000 -20% $0.000000 205,712 03 Jan 2022 Common Stock 53,000 $0.6150 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option vested and became exercisable on September 1, 2019, with the remainder vesting in 36 equal monthly installments thereafter.